Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT – Get Rating) insider Terrie Curran sold 5,821 shares of the company’s stock in a transaction on Friday, January 20th. The shares were sold at an average price of $8.20, for a total value of $47,732.20. Following the sale, the insider now directly owns 176,807 shares of the company’s stock, valued at $1,449,817.40. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Phathom Pharmaceuticals Price Performance
Shares of PHAT stock opened at $8.61 on Monday. Phathom Pharmaceuticals, Inc. has a fifty-two week low of $6.09 and a fifty-two week high of $19.95. The stock’s 50-day moving average is $9.81 and its two-hundred day moving average is $9.77. The firm has a market cap of $358.36 million, a P/E ratio of -1.84 and a beta of 0.29.
Phathom Pharmaceuticals (NASDAQ:PHAT – Get Rating) last issued its earnings results on Tuesday, November 8th. The company reported ($1.32) earnings per share for the quarter. As a group, research analysts expect that Phathom Pharmaceuticals, Inc. will post -5.22 EPS for the current year.
Analyst Ratings Changes
Institutional Inflows and Outflows
Several hedge funds have recently bought and sold shares of PHAT. Ensign Peak Advisors Inc increased its position in Phathom Pharmaceuticals by 51.7% in the 2nd quarter. Ensign Peak Advisors Inc now owns 1,675,488 shares of the company’s stock worth $14,140,000 after purchasing an additional 570,729 shares during the last quarter. Medicxi Ventures Management Jersey Ltd increased its position in Phathom Pharmaceuticals by 18.5% in the 2nd quarter. Medicxi Ventures Management Jersey Ltd now owns 2,450,679 shares of the company’s stock worth $20,684,000 after purchasing an additional 382,818 shares during the last quarter. 683 Capital Management LLC increased its position in Phathom Pharmaceuticals by 15.6% in the 3rd quarter. 683 Capital Management LLC now owns 1,663,943 shares of the company’s stock worth $18,436,000 after purchasing an additional 223,943 shares during the last quarter. Western Standard LLC bought a new stake in shares of Phathom Pharmaceuticals during the 2nd quarter worth about $920,000. Finally, Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of Phathom Pharmaceuticals during the 2nd quarter worth about $6,703,000. 98.57% of the stock is owned by institutional investors and hedge funds.
Phathom Pharmaceuticals Company Profile
Phathom Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach.
- Get a free copy of the StockNews.com research report on Phathom Pharmaceuticals (PHAT)
- CVS Health is Growing into an Integrated Healthcare Organization
- NVIDIA Outlook Improving: Watchlist Candidate for 2023
- Is C3.ai Stock a ChatGPT Artificial Intelligence Play?
- Which Wireless Stock Should You Buy in 2023?
- Is Virgin Galactic Stock Preparing for Lift-Off?
Receive News & Ratings for Phathom Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phathom Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.